Waldencast Clears SEC Probe Over Obagi Accounting Restatement Without Enforcement
Waldencast plc said the SEC will not recommend enforcement after investigating its restatement of financials and internal control weaknesses tied to Obagi Cosmeceuticals. The company voluntarily disclosed the issues, fully cooperated and incurred substantial legal and advisory costs during the probe.
1. SEC Investigation Closure
The SEC concluded its investigation into Waldencast’s restatement of historical financial results and material internal control weaknesses related to Obagi Cosmeceuticals. The SEC will not recommend enforcement action based on available information as of April 28, 2026.
2. Voluntary Disclosure and Costs
Waldencast voluntarily disclosed these matters in its periodic reports and maintained full cooperation throughout the probe. The company dedicated significant resources and incurred substantial legal, advisory and related costs during the investigation.
3. Management Response and Outlook
CEO Michel Brousset highlighted that the favorable outcome removes a regulatory overhang and allows the company to maintain focus on executing its multi-brand beauty strategy. Waldencast affirmed its commitment to strong governance and robust internal controls as it scales high-growth, purpose-driven brands.